| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2021 , Vol 59 , Num 4
Review Article: Pitavastatin: Similarities and Differences Compared With Other Statins
1 Catedra de Riesgo Cardiovascular, Universidad de Salamanca, Salamanca, Spain2 Department of Internal Medicine, Kartal Research and Education Hospital, Istanbul, Turkey
3 Department of Medical Pharmacology, Beykent University- Beykent Faculty of Medicine, Istanbul, Turkey
4 Department of Cardiology, Kelkit State Hospital, Gumushane, Turkey
5 Department of Cardiology, University of Sciences and Research Hospital, Istanbul, Turkey
6 Hospital Universitario de Badajoz. Badajoz. Spain
DOI : 10.23893/1307-2080.APS.05935 Viewed : 18217 - Downloaded : 5262 Dyslipidemia is the leading cause of cardiovascular mortality and morbidity. Reduction of lipids, particularly low- density lipoprotein cholesterol (LDL-C), with statins, significantly decreases the risk of cardiovascular events. Among different statins, pitavastatin, exhibits a peculiar pharmacokinetic and pharmacological profile. Indeed, differently from other statins, pitavastatin: a) is not metabolized by hepatic cytochrome CYP3A4 isoenzyme, therefore has a very low drug-drug interaction; b) has a similar or greater effect on LDL-C, c) is not associated with glucose metabolism impairment, and the risk of new onset diabetes is very low, d) increases high density lipoproteins (HDL) levels and, particularly, improves cholesterol efflux capacity of HDL, d) decreases cardiovascular outcome in primary and secondary prevention. Keywords : Dyslipidemia, statins, pitavastatin, new-onset diabetes, HDL